Agomab Therapeutics NV（AGMB）财务数据AGMBAgomab Therapeutics NV

In the context of the broader market, AGMB competes directly with industry leaders such as FTH and VALN. With a market capitalization of $448.65M, it holds a significant position in the sector. When comparing efficiency, AGMB's gross margin of N/A stands against FTH's N/A and VALN's 9.60%. Such benchmarking helps identify whether Agomab Therapeutics NV is trading at a premium or discount relative to its financial performance.

Agomab's financial performance shows a negative net income of -11.73 million EUR for Q4 2024, with a forward P/E ratio of 0, indicating no earnings expected in the near term. The current ratio is strong at 13.99, suggesting good liquidity, but the company is still operating at a loss.